FDA approves Pfizer’s HYMPAVZI™ for the treatment of hemophilia A and B October 14, 2024 Pharma & Biotech FDA approval of HYMPAVZI™: Advancement in hemophilia treatment with weekly prophylaxis and reduced bleeding risk. Learn more about the safety. Continue Reading
